Nyrada Inc (ASX:NYR) is a new US registered, Australia domiciled pharmaceutical company. Our business is drug discovery and drug development in areas of significant community need in the cardiovascular and neurology fields. Our clinical targets are diseases and conditions affecting large numbers of individuals, where current treatment options are suboptimal, and in some cases, non-existent. The guiding principles driving our commercial strategies are:• Sound scientific rationale• Significant unmet clinical need• Large market opportunity• Low number of competitors• Strong IP protection• Favourable regulatory pathway to approvalNyrada's two main programmes are a cholesterol-lowering drug and a drug to treat brain injury, specifically stroke and traumatic brain injury (TBI).

Website: nyrada.com

Employees: 5 - 9

HQ: N/A

Location: Gordon, NSW, AU

Revenue: Not Available

Nyrada Inc. (ASX: NYR) is a leading biotechnology company that focuses on developing innovative therapeutics for treating various diseases. With a strong commitment to research and development, Nyrada Inc. (ASX: NYR) has been making waves in the healthcare industry. If you're looking for contact information for Nyrada Inc. (ASX: NYR), look no further than ConnectPlex. Our platform offers a comprehensive database of company information, including contact details for key personnel and decision-makers. With ConnectPlex, you can easily connect with people working in Nyrada Inc. (ASX: NYR) and explore potential business opportunities. At ConnectPlex, we understand the importance of accurate and up-to-date contact information. That's why we've developed a sophisticated algorithm that ensures our data is always current and reliable. Our platform is designed to help businesses like yours connect with the right people at Nyrada Inc. (ASX: NYR) and other companies across the globe. With ConnectPlex, you can take your business to the next level and achieve your goals. Start your search for Nyrada Inc. (ASX: NYR) contact information today and discover the power of ConnectPlex.

Nyrada Inc. (ASX:NYR) is a pharmaceutical company focused on drug discovery and development in areas of significant community need, particularly in the cardiovascular and neurology fields. The company's mission is to address diseases and conditions that affect large numbers of individuals, where current treatment options are suboptimal or non-existent. Nyrada's two main programs include a cholesterol-lowering drug and a drug to treat brain injury, specifically stroke and traumatic brain injury (TBI). Led by Chief Executive Officer James Bonnar, Nyrada's approach is guided by sound scientific rationale, significant unmet clinical need, large market opportunity, low number of competitors, strong IP protection, and favourable regulatory pathway to approval. With a strong focus on research and development, Nyrada aims to provide effective and safe treatments for patients in need. The company's website, nyrada.com, provides further information on their programs and mission.

Nyrada Inc. is a new pharmaceutical company that is listed on the Australian stock exchange. They do research and development on drugs for serious health problems that affect a lot of people, like heart disease and brain injuries. They want to create drugs that will work better than the ones currently available and that will help a lot of people. They have two main projects: one to lower cholesterol and another to treat brain injuries caused by strokes and accidents.